Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis

Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi

Clin Mol Hepatol. 2024;30(Suppl):S106-S116. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0371

View: 1957 Download: 103 Web of Science: 1 Crossref: 3

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study

Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon

Clin Mol Hepatol. 2024;30(3):500-514. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0055

View: 3269 Download: 180 Web of Science: 2 Crossref: 3

Correspondence

Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):276-278. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0220

View: 2463 Download: 43

Original Article

Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation

Ying-Nan Tsai, Jia-Ling Wu, Cheng-Hao Tseng, Tzu-Haw Chen, Yi-Ling Wu, Chieh-Chang Chen, Yu-Jen Fang, Tzeng-Huey Yang, Mindie H. Nguyen, Jaw-Town Lin, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(1):98-108. Published online December 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0194

View: 3255 Download: 189 Web of Science: 7 Crossref: 10

Snapshot

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?

Soon Kyu Lee, Jung Hyun Kwon

Clin Mol Hepatol. 2023;29(3):825-827. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0185

View: 3998 Download: 105 Web of Science: 1 Crossref: 1

Original Article

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients

Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You

Clin Mol Hepatol. 2023;29(3):747-762. Published online May 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0121

View: 3700 Download: 162 Web of Science: 5 Crossref: 5

Editorial

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 3752 Download: 103 Web of Science: 2 Crossref: 2

Original Article

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization

Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi

Clin Mol Hepatol. 2016;22(4):458-465. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0054

View: 9935 Download: 137 Web of Science: 10 Crossref: 10

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B

Jaemin Lee, Sun Hong Yoo, Won Sohn, Hyung Woo Kim, Yong Sun Choi, Jung Ho Won, Jin Young Heo, Sang Jong Park, Young Min Park

Clin Mol Hepatol. 2016;22(3):339-349. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0021

View: 12680 Download: 169 Web of Science: 20 Crossref: 22

Correspondence

Expanding Treatment Eligibility for Chronic Hepatitis B: Balancing Benefits, Limitations, and Healthcare Access

Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin

Received December 16, 2024 Accepted December 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.1138 [Accepted]

View: 336 Download: 13

1 |

Viewed By 7410	MAFLD: How is it different from NAFLD?
Viewed By 6994	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5604	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5360	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4788	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 270	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 93	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search